Ralliant (NYSE:RAL) Downgraded to Strong Sell Rating by Zacks Research

11 Feb 2026, 12:46 by Jessica Moore · The Cerbat Gem

Zacks Research lowered shares of Ralliant (NYSE:RAL – Free Report) from a hold rating to a strong sell rating in a research note issued to investors on Monday,Zacks.com reports.

Other research analysts have also issued reports about the stock. Morgan Stanley reissued an “overweight” rating and set a $45.00 price objective on shares of Ralliant in a report on Friday. Weiss Ratings downgraded Ralliant from a “hold (c)” rating to a “sell (d)” rating in a research note on Thursday, February 5th. Barclays lowered their price objective on Ralliant from $60.00 to $52.00 and set an “overweight” rating for the company in a report on Monday. Vertical Research raised Ralliant from a “hold” rating to a “buy” rating and set a $45.00 target price on the stock in a report on Friday, February 6th. Finally, Truist Financial lowered their price target on Ralliant from $62.00 to $49.00 and set a “buy” rating for the company in a report on Friday. Seven investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $50.50.

Get Our Latest Stock Report on Ralliant

Ralliant Trading Down 0.6%

NYSE:RAL traded down $0.28 on Monday, hitting $42.76. 1,018,991 shares of the stock were exchanged, compared to its average volume of 2,023,043. Ralliant has a fifty-two week low of $37.27 and a fifty-two week high of $57.02. The stock has a fifty day moving average of $51.26 and a 200-day moving average of $46.64. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.38. The stock has a market cap of $4.82 billion and a PE ratio of 33.68.

Ralliant (NYSE:RAL – Get Free Report) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $0.69 EPS for the quarter, topping analysts’ consensus estimates of $0.67 by $0.02. The company had revenue of $554.60 million for the quarter, compared to analyst estimates of $543.04 million. The business’s revenue was up 1.2% compared to the same quarter last year. Ralliant has set its Q1 2026 guidance at 0.460-0.520 EPS and its FY 2026 guidance at 2.220-2.420 EPS.

Ralliant Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, March 23rd. Stockholders of record on Monday, March 9th will be given a dividend of $0.05 per share. The ex-dividend date is Monday, March 9th. This represents a $0.20 annualized dividend and a dividend yield of 0.5%. Ralliant’s dividend payout ratio (DPR) is 15.75%.

Insider Transactions at Ralliant

In other news, Director Anelise Angelino Sacks acquired 2,000 shares of the business’s stock in a transaction dated Monday, February 9th. The stock was acquired at an average price of $41.25 per share, for a total transaction of $82,500.00. Following the completion of the acquisition, the director directly owned 5,403 shares in the company, valued at $222,873.75. This represents a 58.77% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, SVP Amir A. Kazmi bought 2,545 shares of the firm’s stock in a transaction that occurred on Friday, February 6th. The shares were purchased at an average cost of $39.27 per share, with a total value of $99,942.15. Following the purchase, the senior vice president directly owned 39,699 shares of the company’s stock, valued at approximately $1,558,979.73. This represents a 6.85% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last 90 days, insiders have bought 5,795 shares of company stock valued at $232,405.

Hedge Funds Weigh In On Ralliant

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. CenterBook Partners LP acquired a new stake in shares of Ralliant during the fourth quarter worth approximately $486,000. SouthState Bank Corp boosted its stake in shares of Ralliant by 48.2% during the 4th quarter. SouthState Bank Corp now owns 1,052 shares of the company’s stock valued at $54,000 after buying an additional 342 shares during the period. Capital World Investors grew its holdings in shares of Ralliant by 6.4% during the 4th quarter. Capital World Investors now owns 1,652,364 shares of the company’s stock valued at $84,122,000 after acquiring an additional 100,000 shares in the last quarter. WINTON GROUP Ltd acquired a new position in shares of Ralliant in the fourth quarter worth $5,728,000. Finally, State of Wyoming raised its holdings in shares of Ralliant by 445,900.0% during the fourth quarter. State of Wyoming now owns 4,460 shares of the company’s stock worth $227,000 after acquiring an additional 4,459 shares in the last quarter.

Key Headlines Impacting Ralliant

Here are the key news stories impacting Ralliant this week:

Positive Sentiment: Insiders bought shares — multiple insiders (Director Anelise Angelino Sacks, Director Kevin Bryant and SVP Amir Kazmi) increased their stakes in early February, which can be read as management confidence and may attract some investors. Insider Buying: Ralliant Director Buys
Positive Sentiment: Vertical Research upgrade — a recent upgrade provides a modest demand signal and offsets some negative analyst commentary. Vertical Research Upgrade
Neutral Sentiment: Mixed analyst actions — some firms trimmed price targets but kept constructive ratings (e.g., Barclays trimmed target but maintained Overweight), leaving a range of opinions that may limit consensus momentum. Barclays Price Target Cut
Neutral Sentiment: Short interest has risen materially (~+58.7% in January to ~3.75M shares, ~3.3% of float) — this increases potential intraday volatility and can amplify moves in either direction depending on flow.
Negative Sentiment: Large non‑cash goodwill impairment ($1.4B) in the Test & Measurement segment and reduced FY‑2026 guidance — a substantive hit to fundamentals that prompted re‑ratings and is a primary driver of investor concern. Goodwill Impairment & Guidance
Negative Sentiment: Multiple securities‑law investigations and shareholder litigation notices have been publicized (several law firms are soliciting claims) tied to the timing/disclosure of the impairment and guidance change — this raises legal, regulatory and reputational risks that can pressure the stock. Investigation Alert
Negative Sentiment: Recent analyst downgrades / negative revisions (including a Zacks downgrade to “strong sell” and other cuts) increase selling pressure and reduce near‑term institutional demand. Zacks Downgrade TickerReport

Ralliant Company Profile

(Get Free Report)

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.